RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA MARKET ANALYSIS

Market News

Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market: Key Developments

• In June 2022, Bristol-Myers Squibb Company, a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved Breyanzi (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with large B-cell lymphoma (LBCL) including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have: refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplant (HSCT) due to comorbidities or age
• In December 2022, Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced the launch of its clonoSEQ Assay to detect minimal residual disease (MRD) in blood for patients with diffuse large B-cell lymphoma (DLBCL). DLBCL is the most common type of non-Hodgkin lymphoma (NHL), affecting more than 100,000 people in the U.S. Disease monitoring is crucial to patient management because DLBCL is an aggressive condition that many patients may be able to recover from.

Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market: Key Trends

• Introduction of relapsed or refractory diffuse large B cell lymphoma drug with advanced technology: Introduction of relapsed or refractory diffuse large B cell lymphoma drug with advanced technology in the market is expected to drive growth of the global relapsed or refractory diffuse large B cell lymphoma market over the forecast period. For instance, on July 11, 2023, Roche, a multinational healthcare company, announced that the European Commission (EC) had granted conditional marketing authorization for Columvi (glofitamab) for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. With this approval, Columvi is the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with the most common and aggressive form of lymphoma following multiple lines of therapy. Columvi has the potential to change the current standard of care in DLBCL. As well as inducing early and long-lasting responses in people with heavily pre-treated or refractory DLBCL, Columvi is designed to be provided for a fixed period of time meaning that people have a target end date for their course of treatment and the possibility of a treatment-free period. It is also a chemotherapy-free treatment option that is off-the-shelf, meaning that people do not have to wait for cell collection and genetic engineering - a multistep process that can take several weeks - before starting treatment. This could be particularly important for patients who are at a high-risk of their disease progressing.